sorry, we can't preview this file

crc-21-0105-s01.pptx (3.7 MB)

Figure S1 from Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC

figure

posted on 2023-04-04, 01:22 authored by Maree C. Faux, Janet Weinstock, Sophia Gogos, Emma Prato, Alexander I. Azimpour, Ryan O'Keefe, Yasmin Cathcart-King, Alexandra L. Garnham, Matthias Ernst, Adele Preaudet, Michael Christie, Tracy L. Putoczki, Michael Buchert, Antony W. Burgess

Xgal and DCLK1 staining of colon crypts from DCLK1-CreERT2 BAC transgenic mice

Funding

Department of Health | National Health and Medical Research Council (NHMRC)

Ludwig Institute for Cancer Research (LICR)

Walter and Eliza Hall Institute (WEHI)

History

ARTICLE ABSTRACT

Colorectal cancer is one of the most common cancers worldwide with limited therapeutic options. APC and other Wnt signaling mutations occur in the majority of colorectal cancers but there are currently no Wnt inhibitors in the clinic. The combination of Wnt pathway inhibition with sulindac provides an opportunity for killing Apc-mutant colon adenoma cells and suggests a strategy for colorectal cancer prevention and new treatments for patients with advanced colorectal cancer.